Skip Nav Destination
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay
Issue Archive
February 20 2014
In this Issue
Table of Contents
INSIDE BLOOD
BLOOD WORK
PLENARY PAPER
PLENARY PAPER
EVIDENCE-BASED FOCUSED REVIEW
HOW I TREAT
CLINICAL TRIALS AND OBSERVATIONS
HEMATOPOIESIS AND STEM CELLS
IMMUNOBIOLOGY
LYMPHOID NEOPLASIA
A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma
Itziar Salaverria,Idoia Martin-Guerrero,Rabea Wagener,Markus Kreuz,Christian W. Kohler,Julia Richter,Barbara Pienkowska-Grela,Patrick Adam,Birgit Burkhardt,Alexander Claviez,Christine Damm-Welk,Hans G. Drexler,Michael Hummel,Elaine S. Jaffe,Ralf Küppers,Christine Lefebvre,Jasmin Lisfeld,Markus Löffler,Roderick A. F. Macleod,Inga Nagel,Ilske Oschlies,Maciej Rosolowski,Robert B. Russell,Grzegorz Rymkiewicz,Detlev Schindler,Matthias Schlesner,René Scholtysik,Carsten Schwaenen,Rainer Spang,Monika Szczepanowski,Lorenz Trümper,Inga Vater,Swen Wessendorf,Wolfram Klapper,Reiner Siebert,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group,for the Molecular Mechanisms in Malignant Lymphoma Network Project and Berlin-Frankfurt-Münster Non-Hodgkin Lymphoma Group
Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?
Aliki Xochelli,Christina Kalpadakis,Anne Gardiner,Panagiotis Baliakas,Theodoros P. Vassilakopoulos,Sarah Mould,Zadie Davis,Evangelia Stalika,George Kanellis,Maria K. Angelopoulou,Neil McIver-Brown,Rachel Ibbotson,Sotirios Sachanas,Penelope Korkolopoulou,Anastasia Athanasiadou,Achilles Anagnostopoulos,Helen A. Papadaki,Theodora Papadaki,Kostas Stamatopoulos,Gerassimos A. Pangalis,David Oscier
Bruton’s tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
Jennifer A. Woyach,Engin Bojnik,Amy S. Ruppert,Matthew R. Stefanovski,Virginia M. Goettl,Kelly A. Smucker,Lisa L. Smith,Jason A. Dubovsky,William H. Towns,Jessica MacMurray,Bonnie K. Harrington,Melanie E. Davis,Stefania Gobessi,Luca Laurenti,Betty Y. Chang,Joseph J. Buggy,Dimitar G. Efremov,John C. Byrd,Amy J. Johnson
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
Brief Report
David W. Scott,George W. Wright,P. Mickey Williams,Chih-Jian Lih,William Walsh,Elaine S. Jaffe,Andreas Rosenwald,Elias Campo,Wing C. Chan,Joseph M. Connors,Erlend B. Smeland,Anja Mottok,Rita M. Braziel,German Ott,Jan Delabie,Raymond R. Tubbs,James R. Cook,Dennis D. Weisenburger,Timothy C. Greiner,Betty J. Glinsmann-Gibson,Kai Fu,Louis M. Staudt,Randy D. Gascoyne,Lisa M. Rimsza
MYELOID NEOPLASIA
PHAGOCYTES, GRANULOCYTES, AND MYELOPOIESIS
PLATELETS AND THROMBOPOIESIS
Characterization of multiple platelet activation pathways in patients with bleeding as a high-throughput screening option: use of 96-well Optimul assay
e-blood
Marie Lordkipanidzé,Gillian C. Lowe,Nicholas S. Kirkby,Melissa V. Chan,Martina H. Lundberg,Neil V. Morgan,Danai Bem,Shaista P. Nisar,Vincenzo C. Leo,Matthew L. Jones,Stuart J. Mundell,Martina E. Daly,Andrew D. Mumford,Timothy D. Warner,Steve P. Watson,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group,on behalf of the UK Genotyping and Phenotyping of Platelets Study Group
TRANSPLANTATION
Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation
Marcelo A. Fernandez-Viña,Tao Wang,Stephanie J. Lee,Michael Haagenson,Mahmoud Aljurf,Medhat Askar,Minoo Battiwalla,Lee-Ann Baxter-Lowe,James Gajewski,Ann A. Jakubowski,Susana Marino,Machteld Oudshoorn,Steven G. E. Marsh,Effie W. Petersdorf,Kirk Schultz,E. Victoria Turner,Edmund K. Waller,Ann Woolfrey,John Umejiego,Stephen R. Spellman,Michelle Setterholm
ERRATA
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
Wild-type MKs adhered to fibronectin reorganize actin filaments (labeled by AF488-phalloidin). The images show confocal acquisition in the plane of the white-labeled nucleus (upper image) and at the base of the same cell in contact with the coverslip, forming stress fibers (lower image). See the article by Pertuy et al on page 1261.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
